Intradermal Injection of Anti-CTLA-4 in Patients With Stage I/II Melanoma
Status:
Completed
Trial end date:
2014-02-27
Target enrollment:
Participant gender:
Summary
This study evaluates the clinical safety and tolerability, and the immunological effects of
local intradermal injection of tremelimumab in patients with clinical stage I/II melanoma
patients undergoing a sentinel node biopsy (SNB). Patients will be treated by local
intradermal injections around the excision site of the primary tumor with escalating doses of
2, 5, 10 or 20 mg tremelimumab.